Şunu aradınız:: fosfolipidosi (Maltaca - İngilizce)

temsirolimus kien assoċjat ma’ fosfolipidosi fil-firien.
temsirolimus has been associated with phospholipidosis in rats.

is-sinifikat ta’ fosfolipidosi fil-bniedem mhux magħruf.
the significance of phospholipidosis in humans is unknown.

sustanzi amfifiliċi temsirolimus kien assoċjat ma ’ fosfolipidosi fil- firien.
amphiphilic agents temsirolimus has been associated with phospholipidosis in rats.

evidenza ultrastrutturali tissuġġerixxi li dan it-tibdil retinali jista’ jkun sekondarju għall-fosfolipidosi.
ultrastructural evidence suggests that these retinal changes may be secondary to phospholipidosis.

fosfolipidosi (vakuwolazzjoni taċ-ċelluli tal-fwied, glandoli adrenali u l- pulmun) seħħet ukoll.
phospholipidosis (vacuolation of the cells of the liver, adrenal gland and lung) also occurred.

ma dehrux effetti mhux mixtieqa waqt studji kliniċi, iżda dehru f’annimali li ġew esposti għal doża daqs dik klinika u jista’ jkollhom rilevanza għall-użu kliniku, kif spjegat: vakwolazzjoni taċ-ċelluli tal- frixa, tħassir tat-tubi testikolari, ulċerazzjoni gastrointestinali, ksur tal-għadam u kallijiet, ematopojesi epatika, u fosfolipidosi pulmonarja.
adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: pancreatic islet cell vacuolation, testicular tubular degeneration, gastrointestinal ulceration, bone fractures and calluses, hepatic haematopoiesis, and pulmonary phospholipidosis.